Although anti-IFN therapies, thalidomide, and HCT might be potential treatment options, the results of this study suggest that further research is necessary to elucidate the mechanism of secondary failures and establish effective treatments for HA20, especially in patients with refractory disease. This evidence concerns the gene IFNA1 and A20 haploinsufficiency.